Kidney diseases are a major cause of debilitating illness and premature morbidity that affect both adults and children.
The loss of kidney function is often progressive and asymptomatic in early stage.
Kidneys play a crucial role in maintaining homeostasis; their dysfunction affects virtually every part of the body. Management of patients with renal disease involves an interdisciplinary approach. There is a strong need to personalize treatment for patients.
An estimated 15% of the United States adult population and up to 13% of the European adult population have Chronic Kidney Diseases (CKD), a prevalence which is expected to grow with an aging population.
Patients with CKD often suffer from other comorbidities, including cardiovascular disease, diabetes mellitus, and heart failure.
In addition to CKD, there are some 200 to 300 renal diseases for which mechanisms are unknown and often have a hereditary component.
Among these rare diseases, renal tubulopathies form a complex group of disorders which result in the inability of the tubule to exercise their functions. Disorders and their severity differ depending on the location within the tubule and the existence, or not, of compensatory pathways.
Co-founder of Advicenne in 2007 and Panntherapi in 2020, he is an expert in the clinical development of innovative products for pharmaceutical and biotech industry. He has conducted many clinical studies and has successfully conducted numerous drug development programs in the field of the central nervous system (CNS) and kidney diseases. In particular, he successfully conducted the proof-of-concept study of the « Blockbuster » duloxetine (Cymbalta, Xeristar, Yentreve), approved by the FDA in 2004. His long history of interactions with the U.S. FDA and European (EMA) regulatory agencies provides Averoa with a strategic regulatory vision that is essential to its development.
